View Archive »
About The Cover
Conjugation of human IL-12 to a DNA/histone-binding antibody increases its half-life and attenuates its ability to stimulate IFN-gamma production. Figure 1 (A) shows a ribbon diagram of NHS-IL12, an immunocytokine consisting of the NHS76 antibody fused to 2 IL-12p70 heterodimers. See Fallon et al.
|
|
Table of Contents
Editorial
|
| IRAK1: oncotarget in MDS and AML |
|
https://doi.org/10.18632/oncotarget.1880
|
| 1699-1700 |
Reviews
|
| Pathways and therapeutic targets in melanoma |
|
https://doi.org/10.18632/oncotarget.1892
|
| 1701-1752 |
Research Papers
|
| Apoptotic circulating tumor cells CTCs in the peripheral blood of metastatic colorectal cancer patients are associated with liver metastasis but not CTCs |
|
https://doi.org/10.18632/oncotarget.1524
|
| 1753-1760 |
|
| Spores of Clostridium engineered for clinical efficacy and safety cause regression and cure of tumors in vivo |
|
https://doi.org/10.18632/oncotarget.1761
|
| 1761-1769 |
|
| Vacciniarelated kinase 1 VRK1 confers resistance to DNAdamaging agents in human breast cancer by affecting DNA damage response |
|
https://doi.org/10.18632/oncotarget.1678
|
| 1770-1778 |
|
| Hypoxia inducible factor1 alpha as a therapeutic target in multiple myeloma |
|
https://doi.org/10.18632/oncotarget.1736
|
| 1779-1792 |
|
| The histone demethylase JMJD1A induces cell migration and invasion by upregulating the expression of the long noncoding RNA MALAT1 |
|
https://doi.org/10.18632/oncotarget.1785
|
| 1793-1804 |
|
| Utilization of Rad51C promoter for transcriptional targeting of cancer cells |
|
https://doi.org/10.18632/oncotarget.1792
|
| 1805-1811 |
|
| Inhibition of HER2Integrin signaling by Cucurbitacin B leads to in vitro and in vivo breast tumor growth suppression |
|
https://doi.org/10.18632/oncotarget.1743
|
| 1812-1828 |
|
| TERT promoter mutations in renal cell carcinomas and upper tract urothelial carcinomas |
|
https://doi.org/10.18632/oncotarget.1829
|
| 1829-1836 |
|
| MET aberrations and cMET inhibitors in patients with gastric and esophageal cancers in a phase I unit |
|
https://doi.org/10.18632/oncotarget.1828
|
| 1837-1845 |
|
| Advanced gynecologic malignancies treated with a combination of the VEGF inhibitor bevacizumab and the mTOR inhibitor temsirolimus |
|
https://doi.org/10.18632/oncotarget.1834
|
| 1846-1855 |
|
| ΔNp63 isoformmediated βdefensin family upregulation is associated with lymphangiogenesis and poor prognosis in patients with squamous cell carcinoma |
|
https://doi.org/10.18632/oncotarget.1819
|
| 1856-1868 |
|
| The immunocytokine NHSIL12 as a potential cancer therapeutic |
|
https://doi.org/10.18632/oncotarget.1853
|
| 1869-1884 |
|
| Biglycan enhances gastric cancer invasion by activating FAK signaling pathway |
|
https://doi.org/10.18632/oncotarget.1871
|
| 1885-1896 |
|
| γtocotrienol inhibits angiogenesisdependent growth of human hepatocellular carcinoma through abrogation of AKT/mTOR pathway in an orthotopic mouse model |
|
https://doi.org/10.18632/oncotarget.1876
|
| 1897-1911 |
|
| Diffuse large Bcell lymphoma with combined TP53 mutation and MIR34A methylation: Another “double hit†lymphoma with very poor outcome |
|
https://doi.org/10.18632/oncotarget.1877
|
| 1912-1925 |
|
| PDGFRα upregulation mediated by Sonic Hedgehog pathway activation leads to BRAF inhibitor resistance in melanoma cells with BRAF mutation |
|
https://doi.org/10.18632/oncotarget.1878
|
| 1926-1941 |
|
| Discovery and validation of an INflammatory PROteindriven GAstric cancer Signature INPROGAS using antibody microarraybased oncoproteomics |
|
https://doi.org/10.18632/oncotarget.1879
|
| 1942-1954 |
|
| A new mosaic pattern in glioma vascularization: exogenous endothelial progenitor cells integrating into the vessels containing tumorderived endothelial cells |
|
https://doi.org/10.18632/oncotarget.1885
|
| 1955-1968 |
|
| CHIP is a novel tumor suppressor in pancreatic cancer and inhibits tumor growth through targeting EGFR |
|
https://doi.org/10.18632/oncotarget.1890
|
| 1969-1986 |
|
| Novel downstream molecular targets of SIRT1 in melanoma: a quantitative proteomics approach |
|
https://doi.org/10.18632/oncotarget.1898
|
| 1987-1999 |
Copyright © 2026 Rapamycin Press LLC dba Impact Journals
Oncotarget ® is a registered trademark of Rapamycin Press LLC
Impact Journals ® is a registered trademark of Rapamycin Press LLC
RAPAMYCIN PRESS ® is a registered trademark of Rapamycin Press LLC
